Repros Therapeutics Inc (RPRX.OQ)
19 Jan 2017
Tue, Nov 8 2016
* Repros Therapeutics In Reports third quarter 2016 financial results
* Repros announces acceptance of dossier for Enclomiphene for secondary hypogonadism by European authorities
* Repros provides phase 2 results showing positive outcomes for oral Proellex in women with moderate to severe Endometriosis
* Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men
BRIEF-Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
* Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million Source text for Eikon: Further company coverage:
- Neurocrine Biosciences Building To A Big 2017
- Biotech Forum Daily Digest: Another Big Gain For Biotech; Some Small Caps On The Move; Relypsa Continues To Roll
- Lipocine Vs. Antares: Who Wins?
- 2016 Outlook: Biotech Bear Market Continues
- Premarket Biotech Digest: Geron On The Move, Repros Tumbles, GlobeImmune Rumors
- Is It All Over For Repros Therapeutics?